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i g h l i g h t s
The metabolism of deoxynivalenol-3-glucoside (D3G) in rats was studied.
Urine and feces were analyzed by a validated LC–MS/MS biomarker method.
D3G was readily hydrolyzed to deoxynivalenol (DON) during digestion.
Most D3G was metabolized by the gut microbiota and recovered in feces.
D3G is of considerably lower toxicological relevance than DON, at least in rats.
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a b s t r a c t
Deoxynivalenol-3--d-glucoside (D3G), a plant metabolite of the Fusarium mycotoxin deoxynivalenol
(DON), might be hydrolyzed in the digestive tract of mammals, thus contributing to the total dietary DON
exposure of individuals. Yet, D3G has not been considered in regulatory limits set for DON for foodstuffs
due to the lack of in vivo data. The aim of our study was to evaluate whether D3G is reactivated in vivo
by investigation of its metabolism in rats. Six Sprague-Dawley rats received water, DON (2.0mg/kg body
weight (b.w.)) and the equimolar amount of D3G (3.1mg/kg b.w.) by gavage on day 1, 8 and 15, respec-
tively. Urine and feces were collected for 48h and analyzed for D3G, DON, deoxynivalenol-glucuronide
(DON-GlcA) and de-epoxy deoxynivalenol (DOM-1) by a validated LC–tandem mass spectrometryDME
rine
eces
odent
(MS/MS) based biomarker method. After administration of D3G, only 3.7±0.7% of the given dose were
found in urine in the form of analyzed analytes, compared to 14.9±5.0% after administration of DON,
and only 0.3±0.1% were detected in the form of urinary D3G. The majority of administered D3G was
recovered as DON and DOM-1 in feces. These results suggest that D3G is little bioavailable, hydrolyzed
to DON during digestion, and partially converted to DOM-1 and DON-GlcA prior to excretion. Our data
indicate that D3G is of considerably lower toxicological relevance than DON, at least in rats.Abbreviations: D3G, deoxynivalenol-3--d-glucoside; DON, deoxynivalenol;
ECFA, Joint FAO/WHO Expert Committee on Food Additives; DOM-1, de-epoxy
eoxynivalenol; DON-GlcA, deoxynivalenol-glucuronide; DOM-1-GlcA, DOM-1-
lucuronide; b.w., body weight; SPE, solid phase extraction; MeOH, methanol; ACN,
cetonitrile; HPLC, high performance liquid chromatography; MS, mass spectrom-
try; MS/MS, tandem mass spectrometry; SRM, selected reaction monitoring; DP,
eclustering potential; CE, collision energy; RA, apparent recovery; SSE, signal sup-
ression/enhancement; RE, recovery of the extraction step; LOD, limit of detection;
OQ, limit of quantiﬁcation; Z14G, zearalenone-14--d-glucoside.
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1. Introduction
The mycotoxin deoxynivalenol (DON), a secondary metabolite
of several Fusarium species, is one of the most important mycotox-
ins in cereal crops worldwide, and the most frequently occurring
type B trichothecene in Europe (SCOOP, 2003). DON inhibits pro-
tein synthesis and modulates immune responses (reviewed by
Pestka, 2010). In animals, toxicity symptoms include feed refusal,
vomiting and growth depression (summarized by Pestka, 2007).
Furthermore, DON causes inhibition of germination and growth
retardation in plants (reviewed by Rocha et al., 2005). However,
plants can metabolize DON to a variable extend through enzy-
matic conjugation to glucose (Berthiller et al., 2009b; Lemmens
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t al., 2005; Poppenberger et al., 2003). The resulting “masked”
ycotoxin deoxynivalenol-3--d-glucoside (D3G) affects protein
iosynthesis to a far lower extent than DON in vitro and is
herefore regarded as a detoxiﬁcation product of DON in plants
Poppenberger et al., 2003).
D3G was ﬁrst detected in naturally contaminated wheat and
aize in 2005 (Berthiller et al., 2005). Since then, the worldwide
ccurrence of D3G in different cereal crops has been reported
Berthiller et al., 2009a; De Boevre et al., 2012; Desmarchelier and
eefelder, 2011; Li et al., 2011; Sasanya et al., 2008). The molar per-
entages of D3G/DON varied strongly in these studies, but reached
aximum levels of 46% (Berthiller et al., 2009a). This percentage
ay increase in the future as a consequence of plant breeding
fforts to enhance Fusarium head blight resistance by introgression
f resistance loci (Lemmens et al., 2005). Considerable amounts of
3G were found in foodstuffs such as breakfast cereals, snacks and
eers (Kostelanska et al., 2009; Malachova et al., 2011). Despite its
requent occurrence, the toxicological relevance of D3G in humans
nd animals has not yet been evaluated. The Joint FAO/WHO Expert
ommittee on Food Additives (JECFA) stressed the possibility that
3G is hydrolyzed in the digestive tract of mammals (JECFA, 2011).
lthough this assumption is not yet supported by in vivo data, a
ecent study showed that certain intestinal bacteria are capable of
leaving D3G to DON in vitro (Berthiller et al., 2011).
Numerous studies have examined the toxicokinetics of DON
n vivo, revealing two major metabolic pathways: de-epoxidation
y anaerobic bacteria and conjugation to glucuronic acid. De-
poxy deoxynivalenol (DOM-1), which is at least 50-fold less toxic
han DON (Sundstøl Eriksen et al., 2004), is formed by anaero-
ic ruminal or intestinal microbes (summarized by Zhou et al.,
008). DOM-1 can be excreted via the feces or it can be absorbed
nd detected in different biological samples of animals, like urine,
lasma (reviewed by Rotter et al., 1996), and milk (Seeling et al.,
006). The ability to detoxify DON to DOM-1 in the upper gas-
rointestinal tract is considered a major cause for the differences
egarding the susceptibility to DON among species (Pestka, 2007;
otter et al., 1996).
The  main metabolic pathway of mammals to detoxify resorbed
ON is glucuronidation, a phase II reaction which reﬂects one
f the most important mechanisms to inactivate xenobiotics by
nhancing their polarity and excretability. Studies in different ani-
al  species showed that deoxynivalenol-glucuronide (DON-GlcA)
s the major DON metabolite in plasma and urine (summarized by
u et al., 2007). In humans, the measurement of urinary DON and
ON-GlcA levels has been used successfully as a biomarker to assess
ON exposure (Turner et al., 2011; Warth et al., 2012a). In addition,
he formation of DOM-1-glucuronide (DOM-1-GlcA) in urine of rats
as recently been reported (Lattanzio et al., 2011).
The presence of characteristic metabolites in urine and in feces
llows conclusions regarding the absorption and metabolism of
ycotoxins (Galtier, 1998). Studies determining the total recovery
f orally administered DON in excreta of rats have been performed
s early as in the 1980s (Lake et al., 1987; Worrell et al., 1989;
oshizawa et al., 1983). Depending on whether DON was  applied
n its pure form or as a radiolabeled compound, observed recov-
ries ranged from around 15 to 89% of the applied toxin dose,
espectively.
D3G has so far not been considered in the regulatory limits
or cereal-based food established by the European Commission for
ON (European Commission, 2006). Yet, JECFA stated that D3G
ight be an important contributor to dietary DON exposure and
mphasized the need of in vivo data concerning the absorption, dis-
ribution, metabolism and excretion (ADME) in order to evaluate
he potential health risk of D3G (JECFA, 2011).
The aim of the present study was to determine the fate of orally
dministered D3G in rats and to compare it with the pattern of DONrs 213 (2012) 367– 373
metabolism.  To this end, urine and feces of D3G and DON treated
rats were analyzed for D3G, DON, DON-GlcA and DOM-1 by a val-
idated LC–tandem mass spectrometry (MS/MS) based biomarker
method. This study provides the ﬁrst insight into the metabolism
and excretion of D3G in vivo, thus contributing to the risk assess-
ment of this masked mycotoxin.
2. Materials and methods
2.1.  Chemicals and standard solutions
Methanol  (MeOH), acetonitrile (ACN) (both LC grade) and glacial acetic acid
(p.a.)  were purchased from VWR  International GmbH (Vienna, Austria). Water was
puriﬁed with a with a Purelab Ultra system (ELGA LabWater, Celle, Germany).
DON and DOM-1 standards were obtained from Romer Labs GmbH (Tulln,
Austria).  D3G was previously puriﬁed from DON treated wheat plants (Berthiller
et  al., 2005) and DON-3-GlcA was chemically synthesized according to the method
developed by Fruhmann et al. (2012). For use as analytical standards, solid com-
pounds (DON, D3G, and DON-3-GlcA) were dissolved in ACN. A mixed stock solution,
containing 100 g/mL DON, D3G, DOM-1 and DON-GlcA, was prepared in ACN and
stored at −20 ◦C. Further dilutions for spiking experiments and liquid standards
were  prepared in MeOH/water (20/80, v/v; feces samples) and ACN/water (10/90,
v/v; urine samples).
2.2.  Animals and study design
Male  Sprague-Dawley rats were obtained from the breeding facility of the Medi-
cal University of Vienna (Himberg, Austria) and allowed to acclimatize for one week.
The rats (5 months old, 250–280 g body weight (b.w.)) were housed individually
in  polycarbonate cages (Tecniplast, Hohenpeißenberg, Germany) under controlled
conditions  (24 ± 1 ◦C, humidity 50 ± 5%, 12 h light/dark cycle). Pelleted feed (R/M-H,
Ssniff,  Soest, Germany) and water were provided ad libitum. The rodent diet was
analyzed for its concentrations of DON and D3G before the start of the experiment.
Using  a repeated measures design, the rats (n = 6) received water, DON
(2.0  mg/kg b.w.) and the equimolar amount (6.8 mol/kg b.w.) of D3G (3.1 mg/kg
b.w.)  by gavage on days 1, 8 and 15 of the experiment, respectively. Stock solu-
tions  of 400 g/mL DON and 619 g/mL D3G were prepared by dissolving the solid
standards  in water. Thereof, volumes of 1.4–1.8 mL  were administered to the rats
according to their weight. Feed was withdrawn 12 h before the treatment. After
administration, the animals were housed individually in polycarbonate metabolic
cages  (Tecniplast, Hohenpeißenberg, Germany) for 48 h. Urine and feces were col-
lected for the periods 0–24 h and 24–48 h after dosing and volumetrically measured
or  weighted, respectively. The samples were frozen at −20 ◦C at the end of the 48 h
period.
The study design was approved by both, the Ethics Committee of the Medical
University  of Vienna and the Austrian Ministry for Science and Research.
2.3.  Sample preparation
Urine samples were centrifuged (10 min, 14,000 × g), acidiﬁed with 1% of acetic
acid  and cleaned up by solid phase extraction (SPE) on Strata C18-T cartridges
(200  mg,  Phenomenex, Aschaffenburg, Germany). After conditioning of the car-
tridges with 5 mL of MeOH and 5 mL  of MeOH/water/acetic acid (5/94/1, v/v/v),
500  L of urine samples containing 1% of acetic acid were applied. Subsequently,
the  cartridges were washed with 1 mL  of MeOH/water/acetic acid (5/94/1, v/v/v).
The analytes were eluted with 2 mL  of MeOH/water/acetic acid (70/29/1, v/v/v) and
the eluates were evaporated to dryness under compressed air. The residues were
reconstituted in 5 mL  of ACN/water (20/80, v/v) for LC–MS/MS analysis.
Feces samples were freeze-dried, homogenized and 250 mg  aliquots were
extracted  three times (40/40/20 min) with MeOH/water (50/50, v/v, 3/2/2 mL)  on a
GFL rotary shaker (Burgwedel, Germany). 500 L aliquots of the pooled raw extracts
were  combined with 500 L cold MeOH.  Subsequently, the solutions were vortexed
for  15 s and centrifuged at 9000 × g for 10 min. Finally, 300 L of the supernatants
was  evaporated to dryness under compressed air and re-dissolved in 300 L of
MeOH/water (20/80, v/v). The samples were vortexed for 30 s and clariﬁed by cen-
trifugation (10 min, 14,000 × g) for LC–MS/MS analysis.
Clean-up procedures for feces and urine as described above resulted in sample
dilutions  by a factor of 56 and 10, respectively.
2.4. HPLC–MS/MS parameters
Analysis was  performed on an 1100 series high performance liquid chromatog-
raphy  (HPLC) system (Agilent Technologies, Waldbronn, Germany) coupled to a
QTrap 4000 LC–MS/MS System (AB Sciex, Foster City, CA) equipped with a Turbo V
electrospray ionization (ESI) source. Chromatographic separation was achieved on
an Atlantis® T3 column (3.0 mm × 150 mm,  3 m, Waters, Vienna, Austria) equipped
with  a 4 mm × 3 mm C18 security guard cartridge (Phenomenex, Torrance, CA, USA).
Eluent  A was  composed of water/acetic acid (99.9/0.1, v/v) and eluent B of ACN/acetic
acid (99.9/0.1, v/v). After an initial period of 2 min  at 5% B, the proportion of B was
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ncreased linearly to 25% (at 3 min), 90% (at 14.8 min) and 96% (at 15 min). After
 hold-time of 2 min  at 96% B, the column was  re-equilibrated for 2 min  at 5% B.
he  temperature of the column oven was  35 ◦C, while the ﬂow rate was set to
00  L/min. The injection volume was 5 L.
Mass spectrometric analysis was performed in the selected reaction monitor-
ng  (SRM) mode after negative electrospray ionization. The following settings were
sed: source temperature 550 ◦C, curtain gas 20 psi, nebulizer gas (GS1) 50 psi, aux-
liary gas (GS2) 50 psi, ion spray voltage −4000 V, collision gas high, SRM dwell time
0 ms.  Mass transitions used for the analysis as well as optimized analyte-dependent
arameters  are given in Table 1.
.5. Method validation
Validation of the method included determination of the apparent recovery (RA),
he signal suppression/enhancement (SSE), the recovery of the extraction step (RE),
he repeatability (RSD) as well as the limits of detection and quantiﬁcation (LODs and
OQs). Feces and urine samples of the control group were spiked in triplicate with
ppropriate amounts of standard mixtures prior to and after extraction. Method
alidation  for feces was  performed for DON, DOM-1 and D3G at 8 different spik-
ng levels, corresponding to a working range of 1–300 ng/mL in the measurement
olutions.  For urine, method performance characteristics were determined for DON,
OM-1, D3G and DON-GlcA in an extended working range of 1–500 ng/mL in the
easurement solutions (9 spiking levels).
.6. Data evaluation
All samples were analyzed using Analyst software version 1.5.2 (AB Sciex, Fos-
er  City, CA). By plotting the peak area versus the analyte concentration in MS Excel
2007), linear regressions curves were obtained for each analyte and sample type.
hereof, the performance characteristics RA and SSE were calculated according to
ulyok et al. (2006). The RE was calculated by dividing the obtained mean values for
he RA by the determined mean values for the SSE. The repeatability of the method,
xpressed  as relative standard deviation, was calculated from the triplicate analysis
f the different spiking levels. The LODs and LOQs were calculated from the spik-
ng levels closest to a signal-to-noise ratio (S/N) of 3:1 and 10:1, respectively, and
ssessed for both, liquid standards and spiked samples.
Urine  and feces samples from treated rats were extracted and analyzed in dupli-
ate.  Sample concentrations were determined on the basis of peak areas using
xternal calibration (Analyst). If samples showed signal-to-noise ratios lower than
:1 and 10:1, respectively, half of the LOD and half of the LOQ values were used
or  further calculations. Obtained mean values were corrected for the RA. The total
mounts of excreted DON, D3G and their metabolites were calculated considering
he  volumes of the urine and the weights of the feces samples, respectively, which
ere collected from the individual rats per day.
. Results and discussion
.1.  Sample preparation and method validation
An LC–MS/MS based method was developed for the direct quan-
iﬁcation of DON, DON-GlcA, DOM-1 and D3G in urine and feces of
ats. Results of the method validation are listed in Table 2.
Urine  was cleaned-up by SPE and diluted before injection.
nitially we tried a dilute-and-shoot approach, as successfully per-
ormed by Warth et al. (2011). However, this procedure did not
ufﬁciently reduce matrix interferences in our samples. Therefore,
PE was employed for sample clean-up. Acidiﬁcation of the solu-
ions used in SPE increased the extraction recoveries. Still, signal
uppression could not be eliminated for all analytes determined in
rine, especially for DOM-1 (27%) and DON (39%). Consequently,
pparent recoveries ranged from 24% (DOM-1) to 89% (DON-GlcA)
see Table 2). In future methods, the use of [13C]-labeled internal
tandards could compensate for this limitation of the method. Still
he repeatability of the method was excellent, with RSDs for all
nalytes ≤4%.
Feces  samples were freeze-dried, extracted, diluted and
njected. During method development it became obvious that one-
tep extraction of feces samples resulted in low and non-repeatable
xtraction recoveries. By performing three subsequent extractions,
he RE was increased to ≥86% for all analytes. Besides protein pre-
ipitation with pure MeOH, dilution of the samples was needed in
rder to further decrease matrix effects. Finally, apparent recover-
es ranging from 56% (D3G) to 77% (DON) were achieved.rs 213 (2012) 367– 373 369
LODs and LOQs corresponded to S/N ratios of 3/1 and 10/1,
respectively. In standard solutions, LODs ranged from 0.1 to
1.8 ng/mL, while LOQs were between 0.4 and 5.9 ng/mL. LODs and
LOQs obtained in urine and feces were, however higher due to the
dilution of the samples by a factor of 10 and 56, respectively. In
urine, LODs for DON, D3G, DON-GlcA and DOM-1 were 27, 5.7, 30
and 51 ng/mL, respectively. Corresponding LOQs of 69, 21, 137 and
170 ng/mL were determined. In freeze-dried feces, LODs and LOQs
for DON, D3G and DOM-1 were 90, 95 and 151 ng/g and 202, 482
and 476 ng/g, respectively. The obtained LODs and LOQs were suf-
ﬁciently low for the measurements of the target analytes relevant
in our study.
Altogether, an extensive validation of the employed method was
performed, which ensured accurate quantiﬁcation of the mycotox-
ins biomarkers in urine and feces samples.
3.2. DON, D3G and their metabolites in urine of treated rats
Concentrations of DON, D3G, DON-GlcA and DOM-1  in the
analyzed urine samples were in the range of 97–2200 ng/mL,
143–239 ng/mL, 265–8750 ng/mL and 285–388 ng/mL, respec-
tively. Daily volumes of urine varied between 11 and 33 mL  per rat.
Table 3 presents the total amounts of DON, D3G and their metabo-
lites excreted in urine in the time periods 0–24 h and 24–28 h after
oral application of water, DON and D3G, respectively. For better
comparability of the results, data are expressed as molar amounts.
Following oral application of water, we detected small amounts
of DON and DON-GlcA in urine of rats. Several rodent diets were
analyzed for DON and D3G already before the start of the exper-
iment. One commercial rodent diet showed reasonably low DON
and D3G concentrations (160 g/kg DON and <30 g/kg D3G) and
therefore was  considered suitable for our study. Since concentra-
tions of DON and DON-GlcA were smaller than the respective limit
of quantiﬁcation in the majority of the measured samples, dietary
DON intake was not of major relevance for the outcome to the
experiment.
In the urine samples of DON exposed rats, DON, DON-GlcA and
DOM-1 were determined. Based on the molar amounts excreted
on both days, 88.2 ± 6.8% of the total urinary metabolites were
eliminated within 24 h after administration. This is in accordance
with previous kinetic studies in rats, where urinary DON  excre-
tion decreased after 24 h (Lake et al., 1987; Meky et al., 2003). High
variations in the amounts of daily excreted analytes were observed.
This effect is probably due to the low absorption of DON in one of
the six rats. In detail, urinary DON excretion of rat number 2 was
26.8 nmol within 24 h after dosing, whereas values between 76.5
and 111 nmol were found with the other rats. Thus, besides param-
eters like species speciﬁcity, the route of administration (both
reviewed by Rotter et al., 1996) and the dose (Goyarts and Dänicke,
2006) also variations between individuals and the status of their
digestion can inﬂuence DON metabolism.
DOM-1 has been identiﬁed as a DON metabolite in rat urine
already in 1983 (Yoshizawa et al., 1983). Since then, data concern-
ing the presence and the amount of urinary DOM-1 excretion in rats
have been inconsistent (Lattanzio et al., 2011; Meky et al., 2003).
In the current experiment, we found elevated DOM-1 concentra-
tions in urine from 5 out of 6 animals. However, considerably lower
amounts of DOM-1 were detected in comparison to DON and DON-
GlcA. Thus, elimination of DON in form of DOM-1 in urine seems to
be of minor relevance, at least in our experiment.
The main urinary metabolite was found to be DON-GlcA, rep-
resenting 63.4 ± 6.4% of the total analytes excreted in urine. Meky
et al. (2003) implicated DON-GlcA as the major urinary metabo-
lite on the basis of indirect quantiﬁcation after hydrolysis of urine
samples. In the study by Lattanzio et al. (2011), the presence
of two  DON-GlcA isomers in rat urine (without further details
370 V.  Nagl et al. / Toxicology Letters 213 (2012) 367– 373
Table 1
Mass  transitions and optimized SRM parameters of the target analytes. Values are given in the order quantiﬁer ion, qualiﬁer ion.
Analyte tRa (min) Precursor ion (m/z) Product ion (m/z) DPb (V) CEc (V)
DON 6.29 355.3 [M+Ac]− 59.1 −40 −30
355.3 [M+Ac]− 265.2 −40 −12
D3G 6.13 517.3 [M+Ac]− 427.3 −60 −28
517.3 [M+Ac]− 457.3 −60 −18
DON-GlcA 6.18 471.3 [M−H]− 112.9 −95 −44
471.3 [M−H]− 265.2 −60 −18
DOM-1 6.68 339.3 [M+Ac]− 59.1 −45 −40
339.3 [M+Ac]− 249.1 −40 −18
a Retention time.
b Declustering potential.
c Collision energy.
Table  2
Method performance characteristics for the matrices urine (n = 27) and feces (n = 24).
Matrix Analyte RAa ± RSD (%) SSEb ± RSD (%) REc ± RSD (%) LODd (ng/mL) LOQe (ng/mL)
Urine DON 34 ± 1 39 ± 5 88 ± 5 2.7 6.9
D3G 45 ± 3 56 ± 10 81 ± 13 0.6 2.1
DON-GlcA 89 ± 4 97 ± 3 92 ± 6 3.0 13.7
DOM-1 24 ±  3 27 ±  9 89 ±  11 5.1 17.0
Feces  DON 77 ± 6 77 ± 2 100 ± 6 1.6 3.6
D3G 56 ± 15 66 ± 5 86 ± 18 1.7 8.6
DOM-1 69 ± 2 63 ± 2 108 ± 2 2.7 8.5
a Apparent recovery.
b Signal suppression/enhancement.
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nc Extraction recovery.
d Limits of detection in spiked measurement solutions.
e Limits of quantiﬁcation in spiked measurement solutions.
oncerning their molecular structures) was postulated. Also Warth
t al. (2012a) recently showed the occurrence of two  DON-GlcA
somers in human urine after DON exposure, identifying both
ON-3-GlcA and DON-15-GlcA. In contrast, in vitro synthesis of
ON-GlcA by rat liver microsomes seemingly resulted only in
ormation of DON-3-GlcA (Wu et al., 2007). In our experiment, iden-
ical retention times and quantiﬁer/qualiﬁer-ratios were observed
or DON-3-GlcA in standard solutions and for DON-GlcA in urine
amples. Additionally, a minor second DON-GlcA peak at later
etention time than DON-3-GlcA was found in the urine of rat num-
er 2 and at even lower concentrations also in the urine of all other
ats. Furthermore, urine samples were analyzed by the LC–MS/MS
ethod developed by Warth et al. (2012a) which allows the sepa-
ation and the quantiﬁcation of DON-3-GlcA and DON-15-GlcA. The
nalysis conﬁrmed the presence of DON-3-GlcA in rat urine, while
ON-15-GlcA was not detected in any sample. The minor peak was
nvestigated by MS/MS  experiments and enzymatic hydrolysis with
-glucuronidase (according to Warth et al., 2012a) and assumed
o be another DON-GlcA isomer. Based on these ﬁndings, we con-
lude that DON is mainly metabolized to DON-3-GlcA in the used
at strain. Conjugation to a – yet unidentiﬁed – other DON-GlcA
which was not quantiﬁed in our experiments) occurred only to
inor extent.
Recently, the occurrence of another DON-metabolite in rat
rine, DOM-1-GlcA, was reported (Lattanzio et al., 2011). After
able 3
otal  amounts of recovered DON, D3G, DON-GlcA and DOM-1 in urine. Mean values ± SD
.0  mg/kg b.w. DON and 3.1 mg/kg b.w. D3G, respectively (6.8 mol  toxin/kg b.w.).
Treatment Time period (h) DON ± SD (nmol) D
Water 0–24 1.3 ± 0.7 n
24–48 1.9 ± 1.6 n
DON 0–24 79 ± 28 n
24–48 10 ± 2.0 n
D3G  0–24 26 ± 4.9 6
24–48 2.4 ± 1.7 0
.d., not detected (analyte concentration in all samples <LOD).enzymatic  hydrolysis of urine samples, we  observed an increase
in the DOM-1 concentration of 2.0- to 3.2-fold, indicating the pres-
ence of DOM-1-GlcA. Yet, direct quantiﬁcation of DOM-1-GlcA was
not possible due to the lack of a suitable standard.
Following oral application of D3G, we detected D3G as well as
DON, DON-GlcA and DOM-1 in rat urine. In principle, after oral
administration an effective gastrointestinal absorption leads to
high urinary excretion of a toxin or its metabolites, whereas fecal
elimination indicates lack of absorption (Galtier, 1998). D3G was
determined in all urine samples collected 0–24 h after administra-
tion, proving that this masked mycotoxin is bioavailable in rats.
Yet, amounts of urinary excreted D3G/day did not exceed 9.9 nmol
Furthermore, only traces of D3G were found after 24 h. Thus, the
absorption of D3G seems to be very limited. Currently, only one pre-
vious study evaluated the fate of mycotoxin glucosides in vivo. In
a feeding experiment with zearalenone-14--d-glucoside (Z14G),
Gareis et al. (1990) did not detect Z14G in urine of swine. Seemingly,
bioavailability of Z14G and D3G differs, as was to be expected.
In  recent years concerns have been raised that cleavage of D3G
could increase total DON intake of individuals. In the urine of the
exposed rats, D3G was mainly eliminated in form of DON and DON-
GlcA (67.7 ± 7.0%). Therefore, our ﬁndings demonstrate that DON
is liberated from D3G in vivo, absorbed and subsequently metabo-
lized to DON-GlcA. Yet, considerably lower amounts of DON and
DON-GlcA were determined in the urine of D3G treated rats in
 (n = 6) are given for the indicated time periods after oral administration of water,
3G ± SD (nmol) DON-GlcA (nmol) DOM ± SD (nmol)
.d. 1.2 ± 0.8 n.d.
.d. 1.1 ± 0.7 n.d.
.d. 180 ± 72 14 ± 6.0
.d. 16 ± 5.9 4.3 ± 1.6
.9 ± 2.2 24 ± 5.0 15 ± 7.3
.2 ± 0.1 1.9 ± 1.1 4.7 ± 1.7
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omparison to DON treatment. Thus, DON exposure due to the
ngestion of D3G seems to be marginal, at least in rats.
.3.  DON, D3G and their metabolites in feces of treated rats
Concentrations of DON and DOM-1 in the analyzed feces
amples were between 217–17,700 ng/mL and 819–7740 ng/mL,
espectively. The daily amounts of freeze-dried feces/animal
anged from 3 to 9 g per animal. The total amounts of excreted
ON, DOM-1 and D3G in feces are given in Table 4.
Independent of the treatment, DON-GlcA was  not detected in
ny of the samples, as expected. Even if one presumes a signif-
cant enterohepatic recycling (biliary excretion of DON-GlcA to
ntestines) complete hydrolysis of the conjugate DON-GlcA by bac-
erial glucuronidase would occur before fecal excretion and before
reezing of the fecal samples.
Similar  to the results obtained from the analysis of urine, traces
f DON were observed in rat feces after administration of water
ue to the dietary DON intake. DOM-1 was not detected in the
eces samples of this group, which could be explained by the higher
ethod’s LODs and LOQs compared to DON and by only partial
onversion.
Following DON application, DON and DOM-1 were found in
at feces. The de-epoxidation of DON by rat gut microbes was
emonstrated by Worrell et al. (1989). Furthermore, DOM-1 was
etermined as the major DON-metabolite in feces (Lake et al., 1987;
orrell et al., 1989; Yoshizawa et al., 1983). In accordance, we
bserved DOM-1 amounts in feces exceeding those of DON in 5 out
f 6 animals. Considerable amounts of DOM-1 (up to 78.1 nmol)
ere excreted even 24–48 after dosing.
In the feces of rats dosed with D3G, the vast majority of the
etabolites (99.5 ± 0.4%) was excreted in form of DON and DOM-
. Only traces of D3G were detected in three out of six samples
–24 h after treatment. These ﬁndings prove that the non-absorbed
roportion of D3G is almost completely cleaved to DON and sub-
equently metabolized to DOM-1 in the gut. Our results are in line
ith in vitro data from Berthiller et al. (2011), who showed that sev-
ral intestinal bacteria have the capability to hydrolyze D3G to DON.
imilarly, Gareis et al. (1990) demonstrated that Z14G is completely
leaved during digestion, indicating that mycotoxin glucosides in
eneral can be deconjugated in the digestive tract of mammals.
We  previously postulated that D3G is hydrolyzed to DON in
istal parts of the intestine, since the toxin was found to be resis-
ant to acidic conditions and several digestive enzymes (Berthiller
t al., 2011). In total, we observed higher amounts of DON in rat
eces after D3G treatment compared to DON treatment. As DON is
ainly absorbed in the small intestine (Dänicke et al., 2004), our
ata lead to the assumption that D3G is hydrolyzed distal there-
rom. However, detected amounts of DON in feces varied over a
ide range (82–427 nmol), which impedes ﬁrm conclusions. Thus,
urther experiments with more speciﬁc study designs are necessary
o verify this hypothesis.
.4.  Total amounts recovered
It  should be emphasized here that the toxins were applied to
he animals by gavage to ensure complete administration. These
onditions are artiﬁcial, compared to the regular uptake of the com-
ounds with feed. Further studies (e.g. with other animal species)
hall take this into account, preferably delivering the compounds
ixed into the diet.
After  DON application, the overall amount of the recoverednalytes was 554 ± 64 nmol, representing 27.6 ± 3.6% of the admin-
stered dose. In urine, 14.9 ± 5.0% of the applied dose were
ecovered, whereas detected analytes in feces accounted for
2.7 ± 3.4% (Fig. 1). The major metabolite was DON-GlcA (9.5%).Fig. 1. Excretion of DON, D3G and their metabolites in urine and feces of rats (n = 6)
treated with DON or D3G. Values are expressed as equivalent percentages of the
administered dose.
Yoshizawa et al. (1983) recovered around 15% of the applied toxin
dose after oral administration of 6 mg/kg DON. These data correlate
well with our own  ﬁndings, especially if taken into account, that
analysis of DON-GlcA was  not implemented in that study. In con-
trast, signiﬁcantly higher recoveries of around 89% were observed
after administration of 10 mg/kg [14C]-DON in rats (Lake et al.,
1987; Worrell et al., 1989). Lake et al. (1987) found 25% and 64% of
the administered dose in urine and feces, respectively, while Meky
et al. (2003) recovered 37% of the applied dose in urine. Hence,
although we  also obtained a lower recovery in urine, the differ-
ences regarding the detected amounts of analytes in feces are more
striking. Several reasons may  account for this phenomenon.
First, DON elimination via feces is not completed within 48 h
after toxin application, as indicated by our own data and demon-
strated by Lake et al. (1987). Therefore, the lower amounts
recovered in feces can be explained to a certain degree by the short
sampling period. Furthermore, the experimental setup, leading to
freezing of feces samples with a delay of up to 48 h, might have an
inﬂuence. Although the analytes included in our analysis are known
to be stable under different cooling conditions (Warth et al., 2012b),
microbial degradation of the analytes before freezing, resulting in
the formation of unknown metabolites, cannot be excluded.
Above  all, excretion was determined on the basis of radioactiv-
ity in the studies using [14C]-labeled DON. As a consequence, the
obtained total recoveries could also include yet unidentiﬁed DON
metabolites. The formation of such unknown metabolites, most
possibly in the distal end of the intestine, has been suggested before
(Sundstøl Eriksen et al., 2003) and would explain the lower recov-
eries of our experiment. Therefore, an important task in the future
will be the evaluation of such metabolites and their subsequent
characterization on a high resolution mass spectrometer.
Nevertheless, by using a repeated measures study design we
clearly focused on the metabolism of D3G in comparison to that
of DON. The total recovery of administered D3G was  20.9 ± 6.6%,
with feces being the main excretory route (17.2 ± 6.6%; Fig. 1).
Only 3.7 ± 0.7% of the applied dose were recovered in urine, with
D3G representing 0.3 ± 0.1%. Thus, our data show that D3G and
its metabolites are considerably less absorbed than DON in rats
and therefore most likely less bioavailable. A lower absorption of
glycosylated plant metabolites in comparison to their parent agly-
cones has been described in the literature before, for instance for
isoﬂavones (reviewed by Mortensen et al., 2009). DON  and DON-
GlcA found in the urine accounted for 1.3 ± 0.3% and 1.2 ± 0.3% of
the administered dose, respectively (2.5 ± 0.1% in total). The other
urinary metabolites D3G and DOM-1 are assumed to possess a
reduced protein synthesis inhibition or a lower cytotoxicity com-
pared to DON (Poppenberger et al., 2003; Sundstøl Eriksen et al.,
2004). In the DON treatment group, urinary DON and DON-GlcA
represented 4.4 ± 1.4% and 9.5 ± 3.6%, which sum up to 13.9 ± 4.7%
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Table 4
Total  amounts of recovered DON, D3G, DON-GlcA and DOM-1 in feces. Mean values ± SD (n = 6) are given for the indicated time periods after oral administration of water,
2.0 mg/kg b.w. DON and 3.1 mg/kg b.w. D3G, respectively (6.8 mol  toxin/kg b.w.).
Treatment Time period (h) DON ± SD (nmol) D3G ± SD (nmol) DON-GlcA (nmol) DOM ± SD (nmol)
Water 0–24 1.9 ± 0.9 n.d. n.d. n.d.
24–48 1.8 ± 0.4 n.d. n.d. n.d.
DON 0–24 77 ± 57 n.d. n.d. 120 ± 29
24–48 5.6 ± 2.3 n.d. n.d. 53 ± 15
D3G  0–24 200 ± 130 1.9 ± 1.5 n.d. 120 ± 33
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D24–48 5.5 ± 3.9 
.d., not detected (analyte concentration in all samples <LOD).
f the administered dose. Therefore, D3G seems to be of reduced
oxicological relevance compared to DON, at least in rats.
In  conclusion, this study demonstrates that D3G is partly
ioavailable in rats. However, the majority of administered D3G
as cleaved during digestion and subsequently excreted in feces.
hus, D3G present in food and feed seems to have a signiﬁcantly
ower toxic equivalency compared to DON. Due to the differences
egarding the anatomy and gut microbiota, the bioavailability and
etabolization may  be species dependent and should be experi-
entally determined in the future. In such follow-up studies, also
he bioavailability of D3G should be monitored, by application of
he substance both orally and into the bloodstream by injection,
ollowed by the determination of its concentration. Currently, the
imited availability of pure D3G precludes testing of larger animals
uch as swine.
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